Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugstore giant Walgreen (NYSE: WAG) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Walgreen's business and see what CAPS investors are saying about the stock right now.

Walgreen facts

Headquarters (Founded)

Deerfield, Ill. (1901)

Market Cap

$27.4 billion

Industry

Drug retail

Trailing-12-Month Revenue

$66.25 billion

Management

CEO Gregory Wasson (since 2009)

CFO Wade Miquelon (since 2008)

Return on Equity (Average, Past 3 Years)

15.7%

Cash/Debt

$2.31 billion / $2.37 billion

Dividend Yield

2%

Competitors

CVS Caremark (NYSE: CVS)

Wal-Mart (NYSE: WMT)

Express Scripts (Nasdaq: ESRX)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 94% of the 2,040 members who have rated Walgreen believe the stock will outperform the S&P 500 going forward. These bulls include All-Stars georcole and TMFDeej, both of whom are ranked in the top 5% of our community.

Just last month, georcole tapped Walgreen as an intriguing income opportunity:

[Walgreen] has grown their dividend on average over the last five years at a 20% clip. ... I know that the recent parting of ways with CVS is going to temporarily hurt some, but [Walgreen] will be fine. I am taking advantage of this situation to pick [Walgreen] while it is down.

Walgreen has since resolved its dispute with CVS over where customers can fill their prescriptions, but the stock hasn't exactly caught fire just yet. While the new contract with CVS is certainly good news, Walgreen continues to face intense pricing pressure from the likes of retail behemoth Wal-Mart, with its $4/month generics program, and pharmacy benefits managers such as Express Scripts, which offer cheap mail-order alternatives. Of course, with as many tailwinds as the pharmacy business, as a whole, has going for it, CAPS All-Star TMFDeej thinks Walgreen is still too attractive to ignore:

Apparently, the chain's recent acquisition of Duane Reade is already paying dividends. Including these newly acquired stores, [Walgreen's] sales rose 8% in June to $5.7 billion. ...

Additionally, pharmacies will have two major trends putting wind in their sails for years to come:

1) an increase in the number of people who have health care coverage and in turn will go to their stores to buy stuff

and

2) the introduction of a huge number of generic drugs over the next several years ... which are significantly more profitable for pharmacies than brand name drugs.

You can even throw in the possible defection away from [Johnson and Johnson's (NYSE: JNJ)] expensive brand-name drugs toward store brand generics after the company's recent quality problems as another possible boon to pharmacies.

What do you think about Walgreen, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!